Skip to main content
Fig. 5 | Clinical Epigenetics

Fig. 5

From: Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer

Fig. 5Fig. 5

Circulating NPTX2 methylation status for monitoring response to therapy and disease progression in mPDAC patients. The left Y-axis represents the percentage of NPTX2 methylation in plasma. Right inner Y-axis represents the RAS mutant allele fraction (MAF, %) and right outer Y-axis represents CA19-9 (U/mL). The different treatments are indicated with different colors, and the shaded intervals indicate the lead time window of NPTX2 in relation to disease progression. Bars indicate Poisson's error (95% CI)

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us